BioDelivery Sciences (BDSI) focuses on developing and commercializing products in the areas of pain management and oncology supportive care. The company uses its patented BioErodible MucoAdhesive (BEMA) and Bioral cochleate drug delivery technologies in the development of its products.

Upcoming Catalyst:

BioDelivery Sciences has created  (BEMA) buprenorphine delivery system known as Bunavail as a low abuse alternative to Suboxone The system Consists of a small piece of bioerodible polymer film that fixes to the inside of the cheek and delivers the drug across the mucous membrane, BEMA has proven to be an effective delivery method with the advantage of being difficult to abuse by smoking, snorting, or injecting. Suboxone tablets just came off the market late last year, leaving Suboxone film the only therapy of its kind on the market for opioid dependance.

The company is anticipating a late June filing of an NDA for Bunavail.

The above chart is very bullish, showing the recent price correction is done, and accumulation is underway. The last wave started at near $4 a share and ran almost to $6. I expect the new wave to move to a pivot price of $5.25 or so. Where it goes from that point will remain to be seen.